Newly-Named KaloBios Pharma (KBIO) CEO Shkreli Briefly Comments on Twitter About Appointment
Incoming KaloBios Pharma (NASDAQ: KBIO) CEO Martin Shkreli posted the following to Twitter late Thursday night:
Martin Shkreli, the Founder and Chief Executive Officer of Turing Pharmaceuticals AG, has acquired 70% of its outstanding shares $KBIO
— Martin Shkreli (@MartinShkreli) November 20, 2015So happy to rescue $KBIO from having to discontinue our promising blood cancer drug lenzilumab. Let's hire the downsized employees back too!
— Martin Shkreli (@MartinShkreli) November 20, 2015